1. Background
2. Objectives
3. Methods
3.1. Strain Collection and Identification
3.2. β-Lactamase Detection and Antimicrobial Susceptibility Test
3.3. Statistical Analysis
4. Results
4.1. Isolates and Distribution
4.2. β-Lactamase Detection and Antimicrobial Susceptibility Test
| Antibiotic | N | R, % | I, % | S, % |
|---|---|---|---|---|
| β-lactamase | 636 | 33.2 | 66.8 | |
| Ampicillin | 640 | 39.1 | 6.6 | 54.4 |
| Amoxycillin-clavulanic acid | 349 | 26.4 | 0 | 73.6 |
| Ampicillin-sulbactam | 641 | 21.8 | 0 | 78.2 |
| Cefuroxime | 640 | 24.8 | 2.5 | 72.7 |
| Ceftriaxone | 350 | 1.7* | 0 | 98.3 |
| Cefotaxime | 288 | 1* | 0 | 99 |
| Meropenem | 632 | 0.2* | 0 | 99.8 |
| Levofloxacin | 640 | 0* | 0 | 100 |
| Sulfamethoxazole-trimethoprim | 641 | 47.7 | 1.4 | 50.9 |
| Azithromycin | 469 | 10.2* | 0 | 89.8 |
| Chloramphenicol | 641 | 1.1 | 0 | 98.9 |
Abbreviations: N, number of isolates; R, resistant; I, intermediate; S, susceptible.
a*, Rate of non-susceptible cases.
| Antibiotic | 2016 | 2017 | 2018 | 2019 | P-Value | ||||
|---|---|---|---|---|---|---|---|---|---|
| N | R, % | N | R, % | N | R, % | N | R, % | ||
| β-lactamase | 148 | 31.8 | 142 | 26.8 | 156 | 35.9 | 192 | 37 | 0.209 |
| Ampicillin | 148 | 33.1 | 145 | 37.2 | 155 | 41.9 | 194 | 42.8 | 0.254 |
| Amoxycillin-clavulanic acid | - | - | - | - | 154 | 23.4 | 194 | 28.9 | 0.249 |
| Ampicillin-sulbactam | 149 | 16.1 | 145 | 26.9 | 155 | 21.3 | 194 | 22.7 | 0.161 |
| Cefuroxime | 149 | 17.4 | 145 | 26.2 | 154 | 23.4 | 194 | 30.4 | 0.048 |
| Ceftriaxone | - | - | - | - | 155 | 1.3* | 194 | 2.1* | 0.582 |
| Cefotaxime | 146 | 1.4* | 143 | 0.7* | - | - | - | - | 0.574 |
| Meropenem | 148 | 0* | 137 | 0.7* | 155 | 0* | 194 | 0* | 0.304 |
| Levofloxacin | 148 | 0* | 145 | 0* | 155 | 0* | 194 | 0* | - |
| Sulfamethoxazole-trimethoprim | 149 | 49 | 145 | 45.5 | 155 | 47.7 | 194 | 48.5 | 0.936 |
| Azithromycin | - | - | - | - | 155 | 7.1* | 191 | 14.7* | 0.027 |
| Chloramphenicol | 149 | 1.3 | 145 | 1.4 | 155 | 0 | 194 | 1.5 | 0.515 |
Abbreviations: N, number of isolates; R, resistant.
a*, Rate of non-susceptible cases.
| Antibiotic | β-Lactamase (+) | β-Lactamase (-) | P-Value | ||||||
|---|---|---|---|---|---|---|---|---|---|
| N | R, % | I, % | S, % | N | R, % | I, % | S, % | ||
| Ampicillin | 211 | 98.6 | 0.5 | 0.9 | 424 | 9.9 | 9.4 | 80.7 | 0.000 |
| Amoxycillin-clavulanic acid | 126 | 38.9 | 0 | 61.1 | 222 | 18.9 | 0 | 81.1 | 0.000 |
| Ampicillin-sulbactam | 212 | 26.9 | 0 | 73.1 | 424 | 19.6 | 0 | 80.4 | 0.046 |
| Cefuroxime | 212 | 33 | 6.6 | 60.4 | 423 | 21 | 0.5 | 78.5 | 0.001 |
| Ceftriaxone | 127 | 3.1* | 0 | 96.9 | 222 | 0.9* | 0 | 99.1 | 0.272 |
| Cefotaxime | 83 | 1.2* | 0 | 98.8 | 201 | 1* | 0 | 99 | 0.626 |
| Meropenem | 210 | 0* | 0 | 100 | 417 | 0.2* | 0 | 99.8 | 0.608 |
| Levofloxacin | 211 | 0* | 0 | 100 | 424 | 0* | 0 | 100 | - |
| Sulfamethoxazole-trimethoprim | 212 | 59.4 | 0.5 | 40.1 | 424 | 42 | 1.9 | 56.1 | 0.000 |
| Azithromycin | 161 | 28* | 0 | 72 | 307 | 1* | 0 | 99 | 0.000 |
| Chloramphenicol | 212 | 3.3 | 0 | 96.7 | 424 | 0 | 0 | 100 | 0.001 |
Abbreviations: N, number of isolates; R, resistant; I, intermediate; S, susceptible.
a*, Rate of non-susceptible cases.
| Antibiotics | N | R, % | I, % | S, % |
|---|---|---|---|---|
| Amoxycillin-clavulanic acid | 22 | 100 | 0 | 0 |
| Ampicillin-sulbactam | 42 | 100 | 0 | 0 |
| Cefuroxime | 42 | 100 | 0 | 0 |
| Ceftriaxone | 22 | 9.1* | 0 | 90.9 |
| Cefotaxime | 20 | 10* | 0 | 90 |
| Meropenem | 36 | 2.8* | 0 | 97.2 |
| Levofloxacin | 42 | 0* | 0 | 100 |
| Sulfamethoxazole-trimethoprim | 42 | 47.6 | 9.5 | 42.9 |
| Azithromycin | 24 | 0* | 0 | 100 |
| Chloramphenicol | 42 | 0 | 0 | 100 |
Abbreviations: N, number of isolates; R, resistant; I, intermediate; S, susceptible.
a*, Rate of non-susceptible cases.
4.3. MDR Pattern
| MDR pattern | No. (%) |
|---|---|
| β-lactams-SXT-AZM | |
| AMP-SXT-AZM | 16 (39.0) |
| AMP-CXM-SXT-AZM | 4 (9.8) |
| AMP-CXM-AMC-SXT-AZM | 3 (7.3) |
| AMP-CXM-SAM-AMC-SXT-AZM | 3 (7.3) |
| AMP-AMC-SXT-AZM | 2 (4.9) |
| AMC-SXT-AZM | 1 (2.4) |
| AMP-CXM-SAM-SXT-AZM | 1 (2.4) |
| SAM-SXT-AZM | 1 (2.4) |
| CXM-SXT-AZM | 1 (2.4) |
| AMP-SAM-AMC-SXT-AZM | 1 (2.4) |
| AMP-CXM-SAM-AMC-CRO-SXT-AZM | 1 (2.4) |
| β-lactams-SXT-CHL | |
| AMP-SXT-CHL | 3 (7.3) |
| AMP-AMC-SXT-CHL | 1 (2.4) |
| AMP-SAM-SXT-CHL | 1 (2.4) |
| AMP-CXM-SXT-CHL | 1 (2.4) |
| β-lactams-SXT-AZM-CHL | |
| AMP-SXT-AZM-CHL | 1 (2.4) |
Abbreviations: AMP, ampicillin; AMC: amoxycillin-clavulanic acid; AZM: azithromycin; CHL: chloramphenicol; CRO: ceftriaxone; CXM: cefuroxime; SAM: ampicillin-sulbactam; SXT: sulfamethoxazole-trimethoprim.